Bayer will reduce internal R & D work on drugs, eliminating hundreds of researchers while turning to its partners to unveil plan to cut 12,000 jobs – Endpoints News

Bayer continues its plans to restructure its R & D activity in the field of drugs and removes 900 internal R & D employees as part of a broadband plan to reduce by 12,000 the total number of 39, employees as part of a global overhaul.

The details of the changes in R & D – a rumor that has been circulating for months – are slim, and we do not know what projects are disappearing. According to their statement, 900 jobs are being researched and developed in the pharmaceutical sector, while another 350 are being cut in a German Factor VIII factory. The focus will now be on drug R & D, reducing internal work while involving external partners to take on more of the burden.

In their statement, the German pharmaceutical company said that its research and development measures "include the accelerated development of the innovation model and a restructuring of internal research and development activities. The resources released by the reduction of internal capacities must be directed towards the reinforcement of the investments in the models of collaborative research and the external innovations. "

We asked a Bayer spokesperson for a detailed explanation of the impact of these changes on the company's life sciences group, which is also considering selling consumer goods and withdrawing from the health care sector. following its acquisition of Monsanto – which is facing its own internal cuts. a trial blizzard besets the new owners.

While Roche is upsetting the hemophilia market with its new drug Hemlibra, Bayer announces that it will close the "Factor VIII facility built in Wuppertal, Germany, and … will concentrate all factor production." Recombinant VIII at Berkeley, CA.

Rumors about a big upheaval in R & D have been circulating until 2018. The Wirtschaftswoche started at the end of May, indicating that the possible reductions could reach 1,000 people in the reorganization. Reuters then announced that job cuts and relocations were being explored as the German pharmaceutical group sought to raise more money to acquire new licensed therapies for its pipeline.